|Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer|
EE Parkes, SM Walker, LE Taggart, N McCabe, LA Knight, R Wilkinson, ...
JNCI: Journal of the National Cancer Institute 109 (1), 2017
|Review of applications of high-throughput sequencing in personalized medicine: barriers and facilitators of future progress in research and clinical application|
G Lightbody, V Haberland, F Browne, L Taggart, H Zheng, E Parkes, ...
Briefings in bioinformatics 20 (5), 1795-1811, 2019
|Automated tumour recognition and digital pathology scoring unravels new role for PD-L1 in predicting good outcome in ER-/HER2+ breast cancer|
MP Humphries, S Hynes, V Bingham, D Cougot, J James, F Patel-Socha, ...
Journal of oncology 2018, 2018
|A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer|
NE Buckley, P Haddock, RDM Simoes, E Parkes, G Irwin, F Emmert-Streib, ...
Oncotarget 7 (15), 19884, 2016
|Validation of the DNA damage immune response signature in patients with triple-negative breast cancer from the SWOG 9313c trial|
P Sharma, WE Barlow, AK Godwin, EE Parkes, LA Knight, SM Walker, ...
Journal of Clinical Oncology 37 (36), 3484, 2019
|Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma|
RC Turkington, LA Knight, JK Blayney, M Secrier, R Douglas, EE Parkes, ...
Gut 68 (11), 1918-1927, 2019
|DNA repair deficiency in breast cancer: opportunities for immunotherapy|
E Gilmore, N McCabe, RD Kennedy, EE Parkes
Journal of oncology 2019, 2019
|Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model|
Y Philippou, HT Sjoberg, E Murphy, S Alyacoubi, KI Jones, ...
British journal of cancer 123 (7), 1089-1100, 2020
|Metastasis and immune evasion from extracellular cGAMP hydrolysis|
J Li, MA Duran, N Dhanota, WK Chatila, SE Bettigole, J Kwon, RK Sriram, ...
Cancer discovery 11 (5), 1212-1227, 2021
|Alcohol intake, tobacco smoking, and esophageal adenocarcinoma survival: a molecular pathology epidemiology cohort study|
RS McCain, DT McManus, S McQuaid, JA James, M Salto-Tellez, ...
Cancer Causes & Control 31 (1), 1-11, 2020
|Clinical tumor staging of adenocarcinoma of the esophagus and esophagogastric junction.|
RC Turkington, E Parkes, RD Kennedy, MM Eatock, C Harrison, ...
Journal of clinical oncology: official journal of the American Society of …, 2015
|Topoisomerase II inhibitors induce cGAS-STING dependent inflammation resulting in cytokine induction and immune checkpoint activation|
RDA Wilkinson, N McCabe, EE Parkes, EM Barros, DI Johnston, RMM Ali, ...
Biorxiv, 764662, 2019
|Development of PARP inhibitors for BRCA-deficient epithelial ovarian cancer|
E Parkes, N McCabe, R Kennedy
Oncogenomics, 521-532, 2019
|Exploring the effect of chemotherapies on STING-dependent cytokine release|
RD Wilkinson, DI Johnston, EE Parkes, N McCabe, RD Kennedy
Cancer Research 78 (13 Supplement), 3787-3787, 2018
|An innate immune response to intrinsic DNA damage predicts resistance to docetaxel in prostate cancer|
CJ Davidson, S Walker, N McCabe, L Hill, E Parkes, S Jain, D O'Rourke, ...
Annals of Oncology 27, vi256, 2016
|Development of immunotherapy combination strategies in cancer|
TA Yap, EE Parkes, W Peng, JT Moyers, MA Curran, HA Tawbi
Cancer Discovery 11 (6), 1368-1397, 2021
|Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer|
F Willenbrock, CM Cox, EE Parkes, CS Wilhelm-Benartzi, AG Abraham, ...
British Journal of Cancer 124 (3), 581-586, 2021
|Identification of a high-risk subgroup in primary prostate cancers presenting with targetable immune biology|
E Reilly, A McCavigan, SM Walker, N McCabe, E Parkes, DP Harkin, ...
Cancer Res 78 (13), 2018
|PD-L1 expression and response to neo-adjuvant chemotherapy in esophageal adenocarcinoma.|
EE Parkes, JK Blayney, E McCarron, RV Douglas, L Stevenson, ...
Journal of Clinical Oncology 35 (15_suppl), 4023-4023, 2017
|Turning the concept of synthetic lethality on its head|
EE Parkes, RD Kennedy
Translational Cancer Research 5 (Suppl 6), S1145-S1148, 2016